Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Aislinn Antrim serves as Managing Editor at Pharmacy Times.

Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...